相似文献
1
FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2.
EMBO J. 2006 Jul 12;25(13):3078-88. doi: 10.1038/sj.emboj.7601198. Epub 2006 Jun 29.
2
Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells.
Oncogene. 2001 Nov 15;20(52):7658-67. doi: 10.1038/sj.onc.1204994.
3
Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling.
Oncogene. 2006 Feb 9;25(6):877-87. doi: 10.1038/sj.onc.1209117.
4
Non-receptor tyrosine kinase Etk is involved in the apoptosis of small cell lung cancer cells.
Exp Mol Pathol. 2010 Jun;88(3):401-6. doi: 10.1016/j.yexmp.2010.02.003. Epub 2010 Mar 4.
5
Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer.
Eur J Cancer. 2010 Feb;46(3):636-41. doi: 10.1016/j.ejca.2009.11.009. Epub 2009 Dec 11.
6
Tumor suppressor PDCD4 represses internal ribosome entry site-mediated translation of antiapoptotic proteins and is regulated by S6 kinase 2.
Mol Cell Biol. 2012 May;32(10):1818-29. doi: 10.1128/MCB.06317-11. Epub 2012 Mar 19.
7
Fibroblast growth factor-inducible 14 regulates cell growth and multidrug resistance of small-cell lung cancer through the nuclear factor-κB pathway.
Anticancer Drugs. 2014 Nov;25(10):1152-64. doi: 10.1097/CAD.0000000000000153.
8
Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo.
Nat Med. 1999 Jun;5(6):662-8. doi: 10.1038/9511.
9
CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells.
Oncogene. 2005 Jun 23;24(27):4462-71. doi: 10.1038/sj.onc.1208621.
10
Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
Cancer Lett. 2010 Sep 1;295(1):110-23. doi: 10.1016/j.canlet.2010.02.019. Epub 2010 Mar 16.
引用本文的文献
1
S6K2 in Focus: Signaling Pathways, Post-Translational Modifications, and Computational Analysis.
Int J Mol Sci. 2024 Dec 28;26(1):176. doi: 10.3390/ijms26010176.
2
Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer.
Mol Cancer. 2024 Nov 15;23(1):256. doi: 10.1186/s12943-024-02167-9.
3
ALYREF recruits ELAVL1 to promote colorectal tumorigenesis via facilitating RNA m5C recognition and nuclear export.
NPJ Precis Oncol. 2024 Oct 25;8(1):243. doi: 10.1038/s41698-024-00737-0.
4
Ribosomal protein S6 kinase 2 (RPS6KB2) is a potential immunotherapeutic target for cancer that upregulates proinflammatory cytokines.
Mol Biol Rep. 2024 Jan 28;51(1):229. doi: 10.1007/s11033-023-09134-5.
5
Angiogenesis in Lung Cancer: Understanding the Roles of Growth Factors.
Cancers (Basel). 2023 Sep 20;15(18):4648. doi: 10.3390/cancers15184648.
6
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Oncologist. 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149.
7
Asymmetric Dimethylation of Ribosomal S6 Kinase 2 Regulates Its Cellular Localisation and Pro-Survival Function.
Int J Mol Sci. 2023 May 15;24(10):8806. doi: 10.3390/ijms24108806.
8
Finding melanoma drugs through a probabilistic knowledge graph.
PeerJ Comput Sci. 2017 Feb 13;3:e106. doi: 10.7717/peerj-cs.106. eCollection 2017.
9
Targeting PEA3 transcription factors to mitigate small cell lung cancer progression.
Oncogene. 2023 Feb;42(6):434-448. doi: 10.1038/s41388-022-02558-6. Epub 2022 Dec 13.
10
Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer.
Cancers (Basel). 2022 Nov 3;14(21):5425. doi: 10.3390/cancers14215425.
本文引用的文献
1
Integrin signaling links protein kinase Cepsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells.
Oncogene. 2004 Nov 11;23(53):8659-72. doi: 10.1038/sj.onc.1207900.
2
PKC controls HGF-dependent c-Met traffic, signalling and cell migration.
EMBO J. 2004 Oct 1;23(19):3721-34. doi: 10.1038/sj.emboj.7600396. Epub 2004 Sep 23.
3
SKAR is a specific target of S6 kinase 1 in cell growth control.
Curr Biol. 2004 Sep 7;14(17):1540-9. doi: 10.1016/j.cub.2004.08.061.
4
S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway.
Mol Cell Biol. 2004 Apr;24(8):3112-24. doi: 10.1128/MCB.24.8.3112-3124.2004.
5
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
Cell. 2004 Mar 19;116(6):855-67. doi: 10.1016/s0092-8674(04)00215-6.
6
Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells.
Mol Cell Biol. 2003 Nov;23(21):7600-10. doi: 10.1128/MCB.23.21.7600-7610.2003.
7
8
Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway.
J Biol Chem. 2003 Oct 24;278(43):42409-18. doi: 10.1074/jbc.M308709200. Epub 2003 Aug 12.
9
Ectopic B-Raf expression enhances extracellular signal-regulated kinase (ERK) signaling in T cells and prevents antigen-presenting cell-induced anergy.
J Biol Chem. 2003 Sep 19;278(38):35940-9. doi: 10.1074/jbc.M301506200. Epub 2003 Jul 10.
10
Protein kinase C phosphorylates ribosomal protein S6 kinase betaII and regulates its subcellular localization.
Mol Cell Biol. 2003 Feb;23(3):852-63. doi: 10.1128/MCB.23.3.852-863.2003.
Zotero 插件